News ReleasesRSS
- Jun 30, 2020 Chugai Files a New Drug Application for Polatuzumab Vedotin for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Jun 29, 2020 Chugai’s Enspryng (Satraliazumab) Subcutaneous Injection 120 mg Syringe Approved in Japan for Neuromyelitis Optica Spectrum Disorder
- Jun 19, 2020 Phase III IPATential150 Study Evaluating Ipatasertib in Combination with Abiraterone and Prednisone/Prednisolone in Patients with Metastatic Castration-Resistant Prostate Cancer Meets One of Its Co-Primary Endpoint
- Jun 18, 2020 Tecentriq in combination with chemotherapy meets primary endpoint, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer
- Jun 05, 2020 Chugai Files for Expanded Use of FoundationOne CDx Cancer Genomic Profile as a Companion Diagnostic of Lynparza for Metastatic Castration-Resistant Prostate Cancer with HRR-Related Gene Alterations
What's NewRSS
- Jun 19, 2020 Evaluation Results of Effectiveness of the Board of Directors
- Jun 08, 2020 Updated FAQs
- May 27, 2020 Events & Presentations has been updated with the Date of the Financial Results for 2Q (Jan-Jun 2020)
- Apr 28, 2020 Updated Message from the CEO
- Apr 24, 2020 Webcast of 1Q Results (Jan-Mar 2020) Conference Call
Share price
Pick Up
For more information
Aiming to be a company where everyone can shine
Feature: Chugai’s Sustainability Activities
Recent Social Contribution Activities
-
Wheelchair Softball Trail Session
-
Contribution to Global Environmental Protection - Efforts to protect water resources through forest maintenance at our production site -
-
Workshop on Multidisciplinary Team Care in Cambodia
